Relationship Between Albuminuria During the First Year and Antibody-Mediated Rejection in Protocol Biopsies in Kidney Transplant Recipients

被引:3
|
作者
Belmar Vega, L. [1 ]
Rodrigo Calabia, E. [1 ]
Gomez Roman, J. J. [2 ]
Ruiz San Millan, J. C. [1 ]
Martin Penagos, L. [1 ]
Arias Rodriguez, M. [1 ]
机构
[1] HU Marques de Valdecilla, Serv Nefrol, Santander, Spain
[2] HU Marques de Valdecilla, Serv Anat Patol, Santander, Spain
关键词
PROTEINURIA; GRAFT;
D O I
10.1016/j.transproceed.2016.09.012
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Background. Antibody-mediated rejection is the main cause of deterioration of kidney transplants and frequently is detected only by means of protocol biopsies. The aim of this study was to relate the presence of albuminuria throughout the 1st year to the histologic findings detected by 1-year protocol biopsies in kidney graft recipients. Methods. Retrospective observational study of 86 protocol biopsies 1 year after transplantation. Albuminuria was measured at 3, 6, 9, and 12 months in urine samples and expressed as albumin/creatinine (mg/g). Results. Analysis of biopsies, reflected according to the Banff criteria, the following categories: fibrosis and tubular atrophy, 35 (40.7%); cellular rejection, 13 (15.1%); antibody-mediated rejection, 8 (9.3%); chronic glomerulopathy, 10 (11.6%); normal, 14 (16.3%); recurrence, 1 (1.2%); and other, 5 (5.8%). The proportions of patients with albuminuria for Banff scale scores (0 vs >= 1, respectively) at 6 and 12 months, respectively, after transplantation, were: for marker glomerulitis, 45.5% versus 59.3% (P = .021) and 36.4% versus 70.4% (P < .001); for marker glomerulopathy, 49.1% versus 50.0% (P = .051) and 42.1% versus 58.3% (P = .019); for marker peritubular capillaritis, 45.8% versus 60.9% (P = .047) and 39.0% versus 69.6% (P = .276); and for marker C4d, 49.2% versus 56.3% (P = .894) and 46.2% versus 56.3% (P = .774). Conclusions. The presence of albuminuria after renal transplantation is common, especially in patients with proteinuria. Persistent albuminuria after transplantation, even at low levels, can be indicative of subclinical antibody-mediated rejection. Additional broader studies to relate the albuminuria to histologic changes observed in protocol biopsies are required.
引用
收藏
页码:2950 / 2952
页数:3
相关论文
共 50 条
  • [41] Transplant glomerulopathy, late antibody-mediated rejection and the ABCD tetrad in kidney allograft biopsies for cause
    Sis, B.
    Campbell, P. M.
    Mueller, T.
    Hunter, C.
    Cockfield, S. M.
    Cruz, J.
    Meng, C.
    Wishart, D.
    Solez, K.
    Halloran, P. F.
    AMERICAN JOURNAL OF TRANSPLANTATION, 2007, 7 (07) : 1743 - 1752
  • [42] Impact of ABO incompatibility and early antibody-mediated rejection on chronic antibody-mediated rejection in kidney transplant patients
    Heo, Ga Young
    Jang, Yunyoung
    Choi, Hyungwook
    Kim, Yong Chul
    Han, Seung Seok
    Kim, Hyung Woo
    Lee, Juhan
    Huh, Kyu Ha
    Kim, Beom Seok
    Yang, Jaeseok
    JOURNAL OF NEPHROLOGY, 2023, 36 (09) : 2571 - 2580
  • [43] Disappearance of T Cell-Mediated Rejection Despite Continued Antibody-Mediated Rejection in Late Kidney Transplant Recipients
    Halloran, Philip F.
    Chang, Jessica
    Famulski, Konrad
    Hidalgo, Luis G.
    Salazar, Israel D. R.
    Lopez, Maribel Merino
    Matas, Arthur
    Picton, Michael
    de Freitas, Declan
    Bromberg, Jonathan
    Seron, Daniel
    Sellares, Joana
    Einecke, Gunilla
    Reeve, Jeff
    JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 2015, 26 (07): : 1711 - 1720
  • [44] Impact of ABO incompatibility and early antibody-mediated rejection on chronic antibody-mediated rejection in kidney transplant patients
    Ga Young Heo
    Yunyoung Jang
    Hyungwook Choi
    Yong Chul Kim
    Seung Seok Han
    Hyung Woo Kim
    Juhan Lee
    Kyu Ha Huh
    Beom Seok Kim
    Jaeseok Yang
    Journal of Nephrology, 2023, 36 : 2571 - 2580
  • [45] Outcomes of a Standardized Antibody-Mediated Rejection (AMR) Treatment Protocol in Heart Transplant Recipients (HTR).
    Lee, J.
    Sam, T.
    Van Zyl, J.
    Mckean, S.
    Fuller, L.
    Wilson, N.
    Dao, A.
    Gottlieb, R.
    Hall, S.
    Patel, R.
    AMERICAN JOURNAL OF TRANSPLANTATION, 2022, 22 : 396 - 396
  • [46] Application of the Banff Human Organ Transplant Panel to kidney transplant biopsies with features suspicious for antibody-mediated rejection
    Beadle, Jack
    Papadaki, Artemis
    Toulza, Frederic
    Santos, Eva
    Willicombe, Michelle
    Mclean, Adam
    Peters, James
    Roufosse, Candice
    KIDNEY INTERNATIONAL, 2023, 104 (03) : 526 - 541
  • [47] Use of Tocilizumab in the treatment of chronic active antibody-mediated rejection in pediatric kidney transplant recipients
    Sangermano, Maria
    Negrisolo, Susanna
    Antoniello, Benedetta
    Vadori, Marta
    Cozzi, Emanuele
    Benetti, Elisa
    HUMAN IMMUNOLOGY, 2024, 85 (05)
  • [48] ECULIZUMAB DECREASES EARLY ANTIBODY-MEDIATED REJECTION IN SENSITIZED DECEASED DONOR KIDNEY TRANSPLANT RECIPIENTS
    Glotz, Denis
    Legendre, Christophe
    Manook, Miriam
    Rostaing, Lionel
    Russ, Graeme R.
    Roelen, Dave
    Nelson, Karen
    Marks, William
    TRANSPLANT INTERNATIONAL, 2013, 26 : 144 - 144
  • [49] Anti-Interleukin 6 Therapeutics for Chronic Antibody-Mediated Rejection in Kidney Transplant Recipients
    Sharma, Rajeev
    EXPERIMENTAL AND CLINICAL TRANSPLANTATION, 2022, 20 (08) : 709 - 716
  • [50] Computational immuno-profiling and prediction of antibody-mediated rejection in kidney transplant recipients.
    Kawakita, Satoru
    Jucaud, Vadim
    Wang, Zhaohui
    Shen, Xiling
    Jiang, Chongming
    TRANSPLANTATION, 2024, 108 (9S)